Clin Mol Hepatol > Epub ahead of print
Shi, Yuan, Fan, and Xu: Correspondence to editorial on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”
Dear Editor,
We sincerely appreciate the insightful comments from Dr. Rezaee-Zavareh regarding our recently published paper titled “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets” [1,2]. These comments not only highlight the strengths of our study but also offer valuable suggestions for future research directions in this field.
As noted in the editorial, the rising prevalence and burden of chronic liver diseases (CLDs) and their related complications, including cirrhosis and hepatocellular carcinoma (HCC), highlight the necessity of identifying risk factors and potential therapeutic targets [3-5]. Our study aimed to contribute to this understanding by investigating the causal role of circulating complement proteins in the risk of non-viral liver diseases using Mendelian randomization (MR) analysis.
Dr. Rezaee-Zavareh’s overview of the existing literature on the crucial roles of complement proteins in liver diseases, including their dual nature in promoting both hepatocyte regeneration and inflammation, provides an excellent context for understanding the significance of our findings. The complex involvement of the complement system in liver disease pathogenesis, particularly in the progression of metabolic dysfunction-associated steatotic liver disease to more advanced stages, as well as in HCC tumorigenesis, metastasis, and immune suppression, highlights the potential of complement-targeted therapies for CLDs [6-8]. The comments highlight the importance of MR as a valuable tool for investigating causal relationships, particularly when randomized controlled trials are not practical or ethically feasible. The examples of previous MR studies reporting causal associations between complement components and various diseases further demonstrate the growing application of this approach to understanding disease causality.
We agree with Dr. Rezaee-Zavareh’s recommendation that future studies should aim to confirm these associations using genome-wide association study data from diverse ancestries to assess their generalizability across different ethnic backgrounds. The heterogeneity observed between the inverse-variance weighted and weighted median methods for some associations highlights the need for additional studies to validate these findings. Furthermore, to gain a more comprehensive understanding of the underlying mechanisms and true nature of the relationships between the studied variables, it is crucial for future research in this field to investigate potential mediators, such as oxidative stress, cytokines, and chemokines.
Regarding our drug repositioning approach, we acknowledge that while we provided some experimental and clinical evidence supporting the identified drugs, further validation using hospital cohort data or clinical trials specifically designed to test these findings is necessary. Our study should be considered an exploratory analysis, and extensive preclinical and clinical studies are required to assess the potential of these drugs for clinical trials.

FOOTNOTES

Authors’ contribution
Y.S. drafted the manuscript. G.Y., X.F., and C.X. contributed to the conception, critical revision, and final approval of the manuscript.
Conflicts of Interest
The authors have no conflicts to disclose.

Abbreviations

CLDs
chronic liver diseases
HCC
hepatocellular carcinoma
MR
Mendelian randomization
MASLD
metabolic dysfunction-associated steatotic liver disease
RCTs
randomized controlled trials
GWAS
genome-wide association study
IVW
inverse-variance weighted
WM
weighted median

REFERENCES

1. Shi Y, Dong H, Sun S, Wu X, Fang J, Zhao J, et al. Proteincentric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets. Clin Mol Hepatol 2024;30:80-97.
crossref pmid pmc pdf
2. Rezaee-Zavareh MS, Kim N, Yang JD. Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization. Clin Mol Hepatol 2024;30:150-153.
crossref pmid pmc pdf
3. Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut 2020;69:564-568.
crossref pmid
4. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol 2023;79:516-537.
crossref pmid
5. Huang DQ, Terrault NA, Tacke F, Gluud LL, Arrese M, Bugianesi E, et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol 2023;20:388-398.
crossref pmid pmc pdf
6. Simbrunner B, Hartl L, Jachs M, Bauer DJM, Scheiner B, Hofer BS, et al. Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis. JHEP Rep 2023;5:100712.
crossref pmid pmc
7. Nguyen VD, Hughes TR, Zhou Y. From complement to complosome in non-alcoholic fatty liver disease: When location matters. Liver Int 2024;44:316-329.
crossref pmid
8. Guo Z, Fan X, Nagy LE, Tomlinson S, Yuan G. Editorial: New insights into the role of complement system in liver diseases. Front Immunol 2023;14:1284944.
crossref pmid pmc

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 693
TOTAL : 2102292
Close layer